At Navolab, we believe in the power of science to ensure every patient receives the treatment that’s right for them—safe, effective, and tailored to promote the fastest possible recovery.
At Navolab, we believe in the power of science to ensure every patient receives the treatment that’s right for them—safe, effective, and tailored to promote the fastest possible recovery.
We develop innovative diagnostic tools to support better treatment decisions, and improved outcomes in immune-mediated and cancer-related conditions.
Tovább
In many cases, multidrug resistance is behind the low effectiveness of medicines.
Billions of dollars are invested globally each year in drug research. Yet despite the growing availability of advanced therapies, many patients with serious conditions still face the harsh reality that their prescribed treatments fall short—delivering limited results and unmet expectations.
In a significant number of cases, this is due to multidrug resistance (MDR)—a complex biological phenomenon where cells actively expel therapeutic compounds, rendering even the most promising medications less effective. Understanding and overcoming MDR is critical to ensuring that patients receive treatments that truly work.
A precision diagnostic device targeting inflammatory bowel disease and rheumatism – a new generation multidrug transporter kit
By directly measuring the activity of key transporter proteins—ABCB1 (P-gp), ABCC1 (MRP1), and ABCG2 (BCRP)—our diagnostic tool provides actionable insights that were previously out of reach. This enables clinicians and researchers to better understand drug resistance patterns at the individual level, leading to more informed treatment decisions and personalized therapy strategies.
With its high sensitivity, speed, and reliability, our solution represents a major step forward in addressing the impact of multidrug resistance in both clinical and research settings.
Oncological diseases, chronic inflammatory, and immune-mediated conditions are a daily ordeal for millions of patients. Even when using well-established therapies, drug resistance remains a significant challenge. Research has revealed that the underlying biochemical mechanisms of disease can vary greatly from patient to patient, leading to differing responses to the same medication.
That’s why there is an urgent need for reliable diagnostic tools that can identify whether a patient is likely to benefit from a specific treatment—or if an alternative approach is necessary.
At Navolab, our mission is to close this gap. By developing innovative diagnostics that reveal critical information about drug response and resistance, we aim to bring greater precision to patient care—ensuring that each individual receives the therapy most likely to help them recover, faster and more effectively.
Therefore, we are constantly researching the transporter proteins present in our cells—ubiquitous across all living organisms—that serve as natural defense mechanisms against toxic or xenobiotic substances. These proteins play a pivotal role in how drugs are absorbed, distributed, and eliminated from the body, and are key factors in the development of drug resistance.
By integrating the latest advances in molecular biology, we are developing the capability to perform highly sensitive laboratory measurements from just a single drop of blood. This allows us to deliver clinically relevant insights that support personalized treatment decisions, particularly for patients managing chronic conditions.
Our goal is clear: to harness cutting-edge molecular and analytical technologies to create a diagnostic tool that can predict how well commonly used medications will work for each individual. In doing so, we hope to transform routine care into truly personalized medicine—improving outcomes, reducing trial-and-error in prescribing, and ultimately enhancing the quality of life for patients worldwide.
The Navolab team is deeply committed to science-based development and the use of the latest technologies. Every day, through our research, we are discovering new properties of the proteins responsible for the emergence of multidrug resistance and our researchers are incorporating this new knowledge into our latest products. Our developments are carried out under a strict quality assurance system, with scientific design, close collaboration and precise, transparent documentation as the key to success.
Navolab was founded on the belief that once the mechanisms behind multidrug resistance were understood, we could begin to measure the functional activity of the key transporter proteins involved—and, most importantly, use this knowledge to optimize drug therapy for individual patients.
This guiding principle drives our innovation. By translating complex biochemical insights into practical diagnostic tools, we aim to bridge the gap between molecular research and clinical application. Our solutions are designed not only to advance scientific understanding but also to directly improve treatment strategies in real-world healthcare settings.
With every step, we move closer to a future where medication is not just prescribed—but precisely matched to each patient’s unique biology, maximizing therapeutic benefit and minimizing unnecessary risks.
Following the evaluation of decades of research on multidrug transporter proteins and the development of a novel diagnostic concept, our research focus has evolved. We are now directing our efforts toward immune-mediated diseases and chronic inflammatory pathologies—areas where drug resistance and variable therapeutic response present significant clinical challenges.
Data generated from our own research has directly informed the design of our new diagnostic kit. As intended, this IVD device demonstrates significantly improved accuracy and reproducibility compared to earlier solutions, setting a new standard in transporter protein analysis.
The development activity resulted in an advanced version of the Theresa kit, which projected the possibility of clinical application.
Investment and capital raising created a solid financial basis for launching clinical validation.
We have initiated clinical trials in a variety of patient groups and in addition, started to enrol healthy volunteers to determine laboratory normal values.
A new clinical trial enrolling pneumonia patients was set up to study the acute phase of inflammation.
We have expanded our development pipeline with a new diagnostic method designed to measure the activity of additional transporter proteins, opening the door to new clinical applications.
This advancement broadens the scope of our technology, enabling us to address a wider range of diseases where transporter activity plays a critical role, and further strengthens our commitment to precision diagnostics in personalized medicine.